Severity More Important than SLE Label in Lupus
Excluding patients with SCLE from clinical trials because they don't meet SLE criteria may not make much sense, researchers report.
Walking Test Can be a Measure of Lung Disease in Lupus
Researchers reporting in the journal Lupus find that a simple walking test can help assess the status of pulmonary disease in patients with systemic lupus erythematosus.
Biologics in Lupus Might have Different Roles at Different Times
With only one approved biologic agent —
Treat-to-Target in Lupus, Not an Impossibility, just Exhaustive
The treat-to-target paradigm has been utilized in RA and other diseases, but not yet lupus. Treat-to-target guidelines in lupus could be complex, but are needed.
Dear Lupus: It’s Time for a Blockbuster Medication
The development of biologic therapies and other treatments for lupus remains a challenge, but anti-interferon agents that are in development could turn things around.
Belimumab: Groundbreaker in Lupus
Belimumab has been a ground-breaking therapy for patients with systemic lupus erythematosus. In this op-ed, Paul Sufka, M.D., reviews recent studies on belimumab which could lead to new uses.
Belimumab with Standard Care Works in Lupus Patients
Belimumab combined with standard of care continues to show positive improvements for patients with systemic lupus erythematosus.
By clicking Accept, you agree to become a member of the UBM Medica Community.